Article information
Full text is only aviable in PDF
REFERENCES
[1]
DJ Balfour.
Neural mechanisms underlying nicotine dependence.
Addiction, 89 (1994), pp. 1419-1423
[2]
G Di Chiara, A Imperato.
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci, 85 (1988), pp. 5274-5278
[3]
WA Corrigall, K Coen, K Adamson.
Self administered nicotine activates the mesolimbic, dopamine system through the ventral tegmental area.
Brain Res, 653 (1994), pp. 278-284
[4]
FE Pointieri, G Tanda, F Orzi, G Di Chiara.
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Nature, 382 (1996), pp. 255-257
[5]
P Kalivas, B Sorg, M Hooks.
The pharmacology and neural circuitry of sensitization to psychostimulants.
Behav Pharmacol, 4 (1993), pp. 315-334
[6]
M Benwell, D Balfour.
The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity.
Br J Pharmacol, 105 (1992), pp. 849-856
[7]
N Benowitz.
Pharmacology of nicotine: addiction and therapeutics.
Annu Rev Pharmacol Toxicol, 36 (1996), pp. 597-613
[8]
Grupo de trabajo de tratamiento del tabaquismo SEPAR.
Normativa para el tratamiento del tabaquismo.
Arch Bronconeumol, 35 (1999), pp. 499-506
[9]
J Anderson, D Jorenby, W Scott, M Fiore.
Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation.
Chest, 121 (2002), pp. 932-941
[10]
I Nerín, A Crucelagui, A Mas, D Guillén.
Perfil de los fumadores que solicitan tratamiento en una unidad de tabaquismo.
Arch Bronconeumol, 93 (2003), pp. 298-302
[11]
National Institute for Clinical Excellence (London). Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance 39, March 2002.
[12]
A Pérez Trullén, M Clemente.
Estado actual y futuras terapias farmacológicas en la deshabituación tabáquica.
Arch Bronconeumol, 37 (2001), pp. 184-196
[13]
S Gourlay, N Benowitz.
Is clonidine an effective smoking cessation therapy?.
Drugs, 50 (1995), pp. 197-207
[14]
LF Stead, JR Hughes.
Lobeline for smoking cessation (Cochrane Review). Cochrane Library, Update Software, (2001),
[15]
T Eissemberg, R Griffiths, M Stitzer.
Mecamylamine does not precipitate withdrawal in cigarette smokers.
Psychopharmacology, 127 (1996), pp. 328-336
[16]
T Lancaster, L Stead.
Individual behavioural counselling for smoking cessation (Cochrane Review). The Cochrane library, Update Software, (2001),
[17]
L Stead, T Lancaster.
Group behavioural therapy programmes for smoking cessation (Cochrane Review). The Cochrane library, Update Software, (2001),
[18]
A US Public Health Service Report.
A clinical practice guideline for treating tobacco use and dependence.
JAMA, 283 (2000), pp. 3244-3254
[19]
JA Ascher, JO Cole, JP Feighner, RM Ferris, HC Fibiger, RN Golden.
Bupropion: a review of its mechanism of antidepressant activity.
J Clin Psychiatry, 56 (1995), pp. 395-401
[20]
DJ Balfour.
The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion.
Int J Clin Pract, 55 (2001), pp. 53-57
[21]
RD Hurt, DP Sachs, ED Glover, KP Offord, JA Johnston, LC Dale, et al.
A comparison of sustained-release bupropion and placebo for smoking cessation.
N Engl J Med, 337 (1997), pp. 1195-1202
[22]
DE Jorenby, SJ Leischow, MA Nides, SI Rennard, JA Johnston, AR Hughes, et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[23]
P Tonnesen, S Tonstad, A Hjalmarson, F Lebargy, P van Spiegel, A Hider, et al.
A multicentre, randomized, double-blind, placebo-controlled, 1 year study of bupropion for smoking cessation.
J Intern Med, 254 (2003), pp. 184-192
[24]
I Sampablo Lauro, L Lores, F Coll, P Rabasa.
Asociación de bupropión y parches de nicotina como terapia para dejar de fumar.
Arch Bronconeumol, 36 (2000), pp. 377-380
[25]
A Tripathi, PA Greenberger.
Bupropion hydrochloride induced serum sickness-like reaction.
Ann Allergy Asthma Inmmunol, 83 (1999), pp. 165-166
[26]
CA Patten, TA Rummans, IT Croghan, RD Hurt, JT Hays.
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports.
J Clin Psychiatry, 60 (1999), pp. 436-441
[27]
M Durcan, G Deener, J White, J Johnston, D Gonzales, R Niaura, et al.
The effect of bupropion sustained-release on cigarette craving after smoking cessation.
Clin Ther, 24 (2002), pp. 540-551
[28]
L Dale, E Glover, D Sachs, D Schroeder, K Offord, I Croghan, et al.
Bupropion for smoking cessation.
Chest, 119 (2001), pp. 1357-1364
[29]
I Sampablo Lauro, JM Carreras, L Lores, M Quesada, F Coll, L Sánchez Agudo.
Deshabituación tabáquica y bupropión: la ansiedad y la depresión como índices de eficacia terapéutica.
Arch Bronconeumol, 38 (2002), pp. 351-355
[30]
JE Henningfield, K Miyasato, DR Jasinski.
Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine.
J Pharmacol Exp Ther, 234 (1985), pp. 1
[31]
NL Benowitz.
Pharmacokinetic considerations in understanding nicotine dependence.
Ciba Found Symp, 152 (1990), pp. 186
[32]
American Psychiatric Association.
Diagnostic and statistical manual of mental disorders, American Psychiatric Association, (1994),
[33]
MC Fine, WC Bailey, SJ Cohen, S Dorfman, MG Goldstein, ER Gritz.
Treating tobacco use and dependence. Clinical practice guideline, US Department of Health and Human Services. Public Health Service, (2000),
[34]
AM Joseph, SM Norman, LH Ferry, et al.
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.
N Engl J Med, 335 (1996), pp. 1792
[35]
Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease.
Nicotine replacement therapy for patients with coronary artery disease.
Arch Intern Med, 154 (1994), pp. 989
[36]
RP Murray, WC Bailey, K Daniels, et al.
Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group.
Chest, 109 (1996), pp. 438
[37]
SE Kimmel, JA Berlin, C Miles, et al.
Risk of acute first myocardial infarction and use of nicotine patches in a general population.
J Am Coll Cardiol, 37 (2001), pp. 1297
[38]
NL Benowitz.
Nicotine replacement therapy during pregnancy.
JAMA, 166 (1991), pp. 3174-3177
[39]
R Wisberg, T Hensikan, N Jespersen Ljorgen.
Nicotine patches for pregnant smokers. A randomised controlled study.
Obstet Gynecol, 96 (2000), pp. 967-971
[40]
KO Fagerström, R Tejding, A Westin, E Lunell.
Aiding reduction of smoking with nicotine replacement medications. Hope for the recalcitrant smokers?.
Tobacco Control, 6 (1997), pp. 311-316
[41]
L Dale, R Hurt, K Offord, G Lawson, I Croghan, D Shroeder.
High dose nicotine patch therapy: percentage of replacement and smoking cessation.
JAMA, 274 (1995), pp. 1353-1358
[42]
T Piasecki, T Baker.
Any further progress in smoking cessation treatment?.
Nicotine Tob Res, 3 (2001), pp. 311
[43]
KO Fagerström.
Combined use of nicotine replacement products.
Health Values, 18 (1994), pp. 15-20
[45]
P Hajek, R West, J Foulds, et al.
Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.
Arch Intern Med, 159 (1999), pp. 2033
[46]
T Lancaster, L Stead, C Silagy, A Sowden.
Effectiveness of interventions to help people stop smoking: findings from the Cochrane library.
BMJ, 321 (2000), pp. 355
[47]
T Blondal.
Contolled trial of nicotine polacrilex gum with supportive measures.
Arch Intern Med, 149 (1989), pp. 1818
[48]
ED Glover, DPL Sachs, ML Stitzer, et al.
Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex.
Am J Health Behavior, 20 (1996), pp. 319
[49]
C Silagy, T Lancaster, L Stead, D Mant, G Fowler.
Nicotine replacement therapy for smoking cessation (Cochrane database of systematic reviews). The Cochrane Library, Update Software, (2003),
[50]
J Hughes, D Hatsukami.
Signs and symptoms of tobacco withdrawal.
Arch Gen Psychiatry, 43 (1986), pp. 289-294
[51]
P Tonnesen, V Fryd, M Hansen, J Heldsted, AB Gunnersen, H Forchammer.
Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomised controlled trial with a 22 month follow-up.
Addict Behav, 13 (1988), pp. 17-27
[52]
N Herrera, R Franco, L Herrera, A Partidas, R Rolando, KO Fagerström.
Nicotine gum, 2 and 4 mg, for nicotine dependence. A double blind placebo controlled trial within a behavior modification support program.
Chest, 108 (1995), pp. 447-451
[53]
M Kortnitzer, F Kittel, M Dramaix, P Bourdoux.
A double blind study of 2 mg versus 4 mg nicotine gum in an industrial setting.
J Psychosom Res, 31 (1987), pp. 171-176
[54]
W Lam, PC Sze, HS Sacks, TC Chalmers.
Meta-analysis of randomised controlled trials of nicotine chewing-gum.
Lancet, 2 (1987), pp. 27
[55]
Pharmacia and Upjohn. Summary of product characteristic for nicorette sublingual tablet 2 mg. 1998.
[56]
S Shiffman, CM Dresler, P Hajek, et al.
Efficacy of a nicotine lozenge for smoking cessation.
Arch Intern Med, 162 (2002), pp. 1267
[57]
MC Fiore, DE Jorenby, TB Baker.
Tobacco dependence and the nicotine patch. Clinical guidelines for effective use.
JAMA, 268 (1992), pp. 2687
[58]
Transdermal Nicotine Study Group.
Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials.
JAMA, 266 (1991), pp. 3133
[59]
N Herrera, R Franco, L Herrera, A Partidas, R Rolando, KO Fagerström.
Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program.
Chest, 108 (1995), pp. 447-451
[60]
P Pusha, H Korhonen, E Vartiainen.
Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia.
Tob Control, 4 (1995), pp. 231-235
[61]
DE Hilleman, SM Mohiuddin, MG Delcore.
Comparison of fixed-dose transdermal nicotine, tapered dose transdermal nicotine, and buspirone in smoking cessation.
J Clin Pharmacol, 34 (1994), pp. 222-224
[62]
MAH Russel, JA Stapleton, C Feyerabend, SM Wiseman, G Gustavsson, U Sawe, et al.
Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches.
BMJ, 306 (1993), pp. 1308-1312
[63]
S Shiffman, CA Elash, SM Paton, CJ Gwaltney, JA Paty, DB Clark.
Comparative efficacy of 24 hour and 16 hour transdermal nicotine patches for relief of morning craving.
Addiction, 95 (2000), pp. 1185-1195
[64]
RL Richmond, L Kehow, AC De Almeida Neto.
Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch.
Heart, 78 (1997), pp. 617
[65]
DM Daughton, SP Fortmann, ED Glover, et al.
The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.
Prev Med, 28 (1999), pp. 113
[66]
JR Hughes, GR Lesmes, DK Hatsukami, RL Richmond, E Lichtenstein, DE Jorenby.
Are higher doses of nicotine replacement more effective for smoking cessation?.
Nicotine Tob Res, 1 (1999), pp. 169-174
[67]
LC Dale, RD Hurt, KP Offord, GM Lawson, IT Croghan, DR Schroeder.
High-dose nicotine patch therapy – percentage of replacement and smoking cessation.
JAMA, 274 (1995), pp. 1353-1358
[68]
DE Jorenby, SS Smith, MC Fiore, RD Hurt, KP Offord, IT Crogham.
Varying nicotine patch dose and type of smoking cessation counselling.
JAMA, 274 (1995), pp. 1347-1352
[69]
P Tonnesen, P Paoletti, G Gustavsson, MA Russell, R Saracci, A Gulsvik.
Higher dosage nicotine patches increase one year smoking cessation rates. Results from the European CEASE trial.
Eur Respir J, 13 (1999), pp. 238-246
[70]
JD Killen, SP Fortmann, L Davis, L Strausberg, A Varady.
Do heavy smokers benefit from higher dose nicotine patch therapy?.
Exp Clin Psychopharmacol, 7226 (1999), pp. 233
[71]
P Paoletti, E Fornai, F Maggiorelli, R Puntoni, G Viegi, L Carrozzi.
Importance of baseline cotinine plasma values in smoking cessation: results from a double blind study with nicotine patch.
Eur Respir J, 9 (1996), pp. 643-651
[72]
JR Hughes, MG Goldstein, RD Hurt, S Shiffman.
Recent advances in the pharmacotherapy of smoking.
JAMA, 281 (1999), pp. 72
[73]
Nicotrol NS® Product Information.
Physician's Desk Reference 1998, Medical Economics, (1998),
[74]
JA Stapleton, G Sutherland, M Russell.
How much does relapse after one year erode effectivenes of smoking cessation treatments? Long term follow up randomised trial of nicotine nasal spray.
Br Med J, 316 (1998), pp. 830-831
[75]
CA Jiménez Ruiz, S Flórez, A Ramos, JJ Lorza, MA Hernández-Mezquita, S Solano Reina, et al.
Tratamiento del tabaquismo con nebulizador nasal de nicotina. Resultados de un estudio multicéntrico.
Arch Bronconeumol, 35 (1999), pp. 535-538
[76]
JE Rose, ED Levin.
Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence.
Pharmacol Biochem Behav, 41 (1991), pp. 219-226
[77]
SJ Leischow, F Nilsson, M Franzon, FV Mody, M Franzon, K Doan.
Efficacy of the nicotine inhaler as an adjunct to smoking cessation.
Am J Health Behav, 20 (1996), pp. 364-371
[78]
NG Schneider, R Olmstead, F Nilsson, FV Mody, M Franzon, K Doan.
Efficacy of nicotine inhaler in smoking cessation: a double blind placebo controlled trial.
Addiction, 91 (1996), pp. 1293-1306
[79]
P Pentel, D Malin, S Ennifar, Y Hieda, D Keyler, J Lake, et al.
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioural and cardiovascular effects in rats.
Pharmacol Biochem Beha, 65 (2000), pp. 191-198
[80]
S de Villiers, N Lindblom, G Kalayanov, S Gordon, A Malmerfelt, A Johansson, et al.
Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell.
Respiration, 69 (2002), pp. 247-253
[81]
N Lindblom, S De Villiers, G Kalayanov, S Gordon, A Johansson, T Svensson.
Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats.
Respiration, 69 (2002), pp. 254-260
[82]
NL Benowitz, P Jacob.
Metabolism of nicotine to cotinine studied by a dual stable isotope method.
Clin Pharmacol Ther, 56 (1994), pp. 483-493
[83]
C Xu, S Goodz, EM Sellers, RF Tyndale.
CYP2A6 genetic variation and potential consequences.
Adv Drug Deliv Rev, 54 (2002), pp. 1245-1256
[84]
Y Rao, E Hoffmann, M Zia, L Bodin, M Zeman, EM Sellers, et al.
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Mol Pharmacol, 58 (2000), pp. 747-755
[85]
EM Sellers, RF Tyndale, LC Fernandes.
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug Discov Today, 8 (2003), pp. 487-493
[86]
DF Gu, LJ Hinks, NE Morton, INM Day.
The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit.
Am Hum Genet., 64 (2000), pp. 383-390
[87]
EM Sellers, HL Kaplan, RF Tyndale.
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Clin Pharmacol Ther, 68 (2000), pp. 35-43
[88]
J Norregaard, S Jorgensen, KL Mikkelsen.
The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.
Clin Pharmacol Ther, 60 (1996), pp. 679-686
[89]
SG Gourlay, NL Benowitz.
Is clonidine an effective smoking cessation therapy?.
Drugs, 50 (1995), pp. 197-207
[90]
M Law, JL Tang.
An analysis of the effectiveness of interventions intended to help people stop smoking.
Arch Intern Med, 155 (1995), pp. 1933-1941
[91]
LS Covey, AH Glassman.
A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation.
Br J Addict, 86 (1991), pp. 991-998
[92]
US Department of Health and human Services.
Clinical practice guideline smoking cessation, US Government Printing Office, (1996),
[93]
G Sutherland, JA Stapleton, MA Russell, C Feyerband.
Naltrexone, smoking behavior and cigarette withdrawal.
Psycopharmacology, 120 (1995), pp. 418-425
[94]
Humfleet G, Hall S, Reus V, Sees K, Muñoz R, Triffleman E. The efficacy of nortriptyline as an adjunct to psychological treatment for smokers with and without depression histories. In: Harris LS, editor. Problems of drug dependence 1995: Proceedings of the 57th Annual Scientific Meeting of the College on Problems of drug dependence, Inc. NDA Research monograph 162. Washington, DC: Government Printing Office, 1996; 334 abstract. (DHHS publication n. [ADM] 96-41116.)
[95]
JK Murphy, NB Edwards, AD Downs.
Effects of doxepin on withdrawal symptoms in smoking cessation.
Am J Psychiatry, 147 (1990), pp. 1353-1357
[96]
NB Edwards, RC Simmons, TL Rosenthal.
Doxepin in the treatment of nicotine withdrawal.
Psychosomatic, 29 (1988), pp. 203-206
[97]
JR Hughes.
Non nicotine pharmacotherapies for smoking cessation.
J Drug Dev, 6 (1994), pp. 197-203
[98]
JS Fowler, ND Volknow, GJ Wang.
Inhibition of monoamine oxidase B in the brains of smokers.
Nature, 379 (1996), pp. 733-737
[99]
TP George, JC Vessicchio, A Termine, PI Jatlow, TR Kosten, SS O'Malley.
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.
Biol Psychiatry, 53 (2003), pp. 136-143
[100]
I Berlin, S Said, O Spreux-Varoquaux.
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy dependent smokers.
Clin Pharmacol Ther, 58 (1995), pp. 444-452
[101]
B Hitsman, R Pingitore, B Spring, A Mahableshwarkar, JS Mizes, KA Segraves, et al.
Antidepressant pharmacotherapy helps some cigarette smokers more than others.
J Consult Clin Psychol, 67 (1999), pp. 547-554
[102]
PM Cinciripini, L Lapitsky, S Seay, A Wallfish, WJ Meyer, H van Vunakis.
A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high and low anxiety smokers.
J Clin Psychopharmacol, 15 (1995), pp. 182-191
[103]
JE Rose, FM Behm.
Inhalation of vapor from black peper extract reduces smoking withdrawal symptoms.
Drug Alcohol Depend, 34 (1994), pp. 225-229
[104]
R Malcolm.
Silver acetate gum as a smoking deterrent.
Chest, 89 (1986), pp. 107-111
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
